Abstract
Epinephrine and Norepinephrine, typically released during stress bind to nine different adrenoceptors (AR) which classically control the cardiovascular and respiratory systems. New targets were described for the many agonists and antagonists developed for these AR, as the central nervous system. During the last three decades, AR expression and action on the mammary gland/breast were extensively investigated. In the cow mammary gland, good milkability was associated with low density of β2-AR and high density of α2-AR. In the rat normal mammary gland, β-AR are expressed in the epithelial cells, alveoli, ducts, and adipocytes showing an exquisite regulation by steroid hormones and prolactin. In rat dimethylbenz(a)anthracene (DMBA) tumors, a close correlation was observed between tumor growth and β-AR concentration. β2-AR were described in numerous human cell lines and breast tumors. The action of β-adrenergic compounds on cell proliferation is contradictory. While some authors found that β-agonists significantly inhibit cancer cell proliferation and tumor growth in mice, others described a significant reduction in DNA synthesis by β-blockers. Also, positive effects of β-AR on human carcinoma cell migration have been described. α2-AR are expressed in human breast cancer and non-cancer cell lines, their stimulation being associated with increased cell proliferation. In vivo clonidine increased tumor growth and α2-adrenergic antagonists completely reversed this effect. When administered alone, rauwolscine inhibited tumor growth behaving as an inverse agonist. Therefore, the numerous adrenergic β- and α-AR agonists or antagonists could prove to be unexpected therapeutic options for mammary gland/ breast and mainly breast cancer.
Keywords: Beta-adrenoceptors, alpha-adrenoceptors, normal breast, breast cancer, mammary tumor
Current Medicinal Chemistry
Title: Adrenoceptors: Non Conventional Target for Breast Cancer?
Volume: 16 Issue: 15
Author(s): I A. Luthy, A. Bruzzone, C. Perez Pinero, L. F. Castillo, I. J. Chiesa, S. M. Vazquez and M. G. Sarappa
Affiliation:
Keywords: Beta-adrenoceptors, alpha-adrenoceptors, normal breast, breast cancer, mammary tumor
Abstract: Epinephrine and Norepinephrine, typically released during stress bind to nine different adrenoceptors (AR) which classically control the cardiovascular and respiratory systems. New targets were described for the many agonists and antagonists developed for these AR, as the central nervous system. During the last three decades, AR expression and action on the mammary gland/breast were extensively investigated. In the cow mammary gland, good milkability was associated with low density of β2-AR and high density of α2-AR. In the rat normal mammary gland, β-AR are expressed in the epithelial cells, alveoli, ducts, and adipocytes showing an exquisite regulation by steroid hormones and prolactin. In rat dimethylbenz(a)anthracene (DMBA) tumors, a close correlation was observed between tumor growth and β-AR concentration. β2-AR were described in numerous human cell lines and breast tumors. The action of β-adrenergic compounds on cell proliferation is contradictory. While some authors found that β-agonists significantly inhibit cancer cell proliferation and tumor growth in mice, others described a significant reduction in DNA synthesis by β-blockers. Also, positive effects of β-AR on human carcinoma cell migration have been described. α2-AR are expressed in human breast cancer and non-cancer cell lines, their stimulation being associated with increased cell proliferation. In vivo clonidine increased tumor growth and α2-adrenergic antagonists completely reversed this effect. When administered alone, rauwolscine inhibited tumor growth behaving as an inverse agonist. Therefore, the numerous adrenergic β- and α-AR agonists or antagonists could prove to be unexpected therapeutic options for mammary gland/ breast and mainly breast cancer.
Export Options
About this article
Cite this article as:
Luthy A. I, Bruzzone A., Pinero Perez C., Castillo F. L., Chiesa J. I., Vazquez M. S. and Sarappa G. M., Adrenoceptors: Non Conventional Target for Breast Cancer?, Current Medicinal Chemistry 2009; 16 (15) . https://dx.doi.org/10.2174/092986709788186048
DOI https://dx.doi.org/10.2174/092986709788186048 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial
Recent Patents on Anti-Cancer Drug Discovery Selection of a GPER1 Ligand via Ligand-based Virtual Screening Coupled to Molecular Dynamics Simulations and Its Anti-proliferative Effects on Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Molecular Classification of Breast Carcinoma In Situ
Current Genomics The Novel RARβ Isoform (β 5) is a Potential Target of Retinoids in Breast Cancer
Current Cancer Drug Targets miRNAs Highlights in Stem and Cancer Cells
Mini-Reviews in Medicinal Chemistry Lessons from the Drug Discovery of Lapatinib, a Dual ErbB1/2 Tyrosine Kinase Inhibitor
Current Topics in Medicinal Chemistry lGnRH-III - a Promising Candidate for Anticancer Drug Development
Protein & Peptide Letters In Vitro and In Vivo Investigations into the Carbene Gold Chloride and Thioglucoside Anticancer Drug Candidates NHC-AuCl and NHC-AuSR
Letters in Drug Design & Discovery Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry The Immunosuppressive Role of Adenosine A2A Receptors in Ischemia Reperfusion Injury and Islet Transplantation
Current Diabetes Reviews Identification of Novel Agents for the Treatment of Brain Metastases of Breast Cancer
Current Cancer Drug Targets Molecular Targeted Approaches to Cancer Therapy and Prevention Using Chalcones
Current Cancer Drug Targets Cucurbitacins as Inducers of Cell Death and a Rich Source of Potential Anticancer Compounds
Current Pharmaceutical Design Opioids and the Blood-Brain Barrier: A Dynamic Interaction with Consequences on Drug Disposition in Brain
Current Neuropharmacology Cutaneous Melanoma: A Test Field for Immunotherapy and a Medical Challenge
Current Cancer Therapy Reviews QSAR Study and Design of Novel Organoselenium and α-Tocopherol Derivatives with Enhanced Chemotherapeutic Activity
Letters in Drug Design & Discovery Current Therapeutic Alternatives and New Perspectives in Glioblastoma Multiforme
Current Medicinal Chemistry Application of Metabolomics in Drug Discovery, Development and Theranostics
Current Metabolomics Vitamin D Analogs in Cutaneous Malignancies
Current Pharmaceutical Design Progress in Nutritional and Health Profile of Milk and Dairy Products: A Novel Drug Target
Endocrine, Metabolic & Immune Disorders - Drug Targets